{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:44:08Z","timestamp":1780393448480,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005075","name":"Universitair Medisch Centrum Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Daiichi Sankyo International"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03033-2","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:17:11Z","timestamp":1731399431000},"page":"322-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-9870","authenticated-orcid":false,"given":"Jeroen Hendrikus Jacobus","family":"Paulissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-3554","authenticated-orcid":false,"given":"Alexander Victor","family":"van Schoonhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-5851","authenticated-orcid":false,"given":"Emma","family":"Olin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan Jacobus","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharie","family":"Mbanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle John","family":"Dunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten Jacobus","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3216-7246","authenticated-orcid":false,"given":"Marinus","family":"van Hulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9458-1832","authenticated-orcid":false,"given":"Roel Donald","family":"Freriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"3033_CR1","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today Lyon, France: International Agency for Research on Cancer 2024. https:\/\/gco.iarc.who.int\/today. Accessed 7 Mar 2024."},{"key":"3033_CR2","unstructured":"Global cancer data by country World Cancer Research Fund International. https:\/\/www.wcrf.org\/cancer-trends\/global-cancer-data-by-country\/#:~:text=The%20highest%20cancer%20rate%20for,(New%20Caledonia)%20and%20Slovenia. Accessed 7 Dec 2023."},{"key":"3033_CR3","unstructured":"International Agency for Research on Cancer. NORDCAN Association of the Nordic Cancer - Denmark Breast 2023 https:\/\/gco.iarc.fr\/media\/nordcan\/factsheets\/93\/en\/countries\/208\/breast-180-denmark-208.pdf. Accessed 7 Mar 2024."},{"key":"3033_CR4","doi-asserted-by":"publisher","unstructured":"Li Y, Tsang JY, Tam F, Loong T, Tse GM. Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment. eBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104571","DOI":"10.1016\/j.ebiom.2023.104571"},{"key":"3033_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"issue":"1","key":"3033_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"3033_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.19.02488.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3033_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13058-023-01739-9","volume":"25","author":"K Nielsen","year":"2023","unstructured":"Nielsen K, Sode M, Jensen MB, et al. High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients. Breast Cancer Res. 2023;25(1):139. https:\/\/doi.org\/10.1186\/s13058-023-01739-9.","journal-title":"Breast Cancer Res"},{"key":"3033_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. 2021. https:\/\/doi.org\/10.1038\/s41523-020-00208-2.","journal-title":"npj Breast Cancer"},{"key":"3033_CR10","unstructured":"European Medicines Agency. Enhertu (trastuzumab deruxtecan) - EMA\/433561\/2023 2023. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/enhertu-epar-medicine-overview_en.pdf. Accessed 5 Mar 2024."},{"key":"3033_CR11","unstructured":"U.S. Food and Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer. Accessed 5 Mar 2024."},{"key":"3033_CR12","doi-asserted-by":"publisher","unstructured":"ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May\u00a02023. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"3033_CR13","unstructured":"Danish Breast Cancer Group. Systemisk behan dling af brystkr\u00e6ft III\u2014palliativ og systemisk behandling af metastaserende brystkr\u00e6ft (MBC) v2.1 2024. Available from: https:\/\/www.dmcg.dk\/globalassets\/generel-overflytning\/dmcg\/retningslinjer---2\/godkendte-kr\/dbcg\/dbcg_pall-syste-bhmbc_v.2.1_admgodk_211024.pdf."},{"issue":"4","key":"3033_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10198-023-01617-3","volume":"25","author":"JHJ Paulissen","year":"2023","unstructured":"Paulissen JHJ, Seddik AH, Dunton KJ, et al. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and\/or metastatic breast cancer in Finland. Eur J Health Econ. 2023;25(4):689\u201399. https:\/\/doi.org\/10.1007\/s10198-023-01617-3.","journal-title":"Eur J Health Econ"},{"key":"3033_CR15","unstructured":"Medicinr\u00e5det. The Danish Medicines Council methods guide for assessing new pharmaceuticals v1.2. Available from: https:\/\/medicinraadet.dk\/media\/wq0dxny2\/the_danish_medicines_council_methods_guide_for_assessing_new_pharmaceuticals_version_1-2_adlegacy.pdf."},{"issue":"12","key":"3033_CR16","doi-asserted-by":"publisher","first-page":"S344","DOI":"10.1016\/j.jval.2023.09.1815","volume":"26","author":"R Svensson","year":"2023","unstructured":"Svensson R, Shire I, Vitor C, Carlqvist P. HTA131 Cost-effectiveness threshold in Denmark's new health technology assessment process: what do we know so far? Value Health. 2023;26(12):S344. https:\/\/doi.org\/10.1016\/j.jval.2023.09.1815","journal-title":"Value Health"},{"key":"3033_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022. https:\/\/doi.org\/10.1186\/s12916-021-02204-0.","journal-title":"BMC Med"},{"key":"3033_CR18","unstructured":"European Medicines Agency. Enhertu (trastuzumab deruxtecan)\u2014EMA\/433561\/2023\u2014summary of product characteristics. 2023."},{"issue":"4","key":"3033_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40258-021-00639-3","volume":"19","author":"CE Jensen","year":"2021","unstructured":"Jensen CE, S\u00f8rensen SS, Gudex C, Jensen MB, Pedersen KM, Ehlers LH. The Danish EQ-5D-5L value set: a hybrid model using cTTO and DCE data. Appl Health Econ Health Policy. 2021;19(4):579\u201391. https:\/\/doi.org\/10.1007\/s40258-021-00639-3.","journal-title":"Appl Health Econ Health Policy"},{"key":"3033_CR20","doi-asserted-by":"crossref","unstructured":"Ueno NT, Jacot W, Yamashita T, et al. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase\u00a0III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC). Ann Oncol. 2022;33(Suppl 7):S632\u2013S633.","DOI":"10.1016\/j.annonc.2022.07.256"},{"key":"3033_CR21","unstructured":"Latimer N. NICE DSU Technical Support Docu ment 14: Undertaking survival analysis for eco nomic evaluations alongside clinical trials-extrapolation with patient-level data. 2011 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf."},{"key":"3033_CR22","unstructured":"L\u00e6gemiddelstyrelsen Danish Medicines Agency. Available from: https:\/\/medicinpriser.dk\/."},{"key":"3033_CR23","unstructured":"Medicinr\u00e5dets anbefaling vedr. trastuzumab der uxtecan til behandling af voksne patienter med ikke-resekterbar eller metastatisk HER2-positiv brystkr\u00e6ft, som har f\u00e5et en eller flere tidligere anti HER2baserede regimer. 2023. Available from: https:\/\/medicinraadet.dk\/anbefalinger-ogvejledninger\/laegemidler-og-indikationsudvidelser\/t\/trastuzumab-deruxtecan-enhertu-brystkraeft."},{"key":"3033_CR24","unstructured":"Sundhedsdatastyrelsen. Takstsystem. 2023. Available from: https:\/\/sundhedsdatastyrelsen.dk\/da\/afregning-og-finansiering\/taksterdrg\/takster-2023."},{"key":"3033_CR25","unstructured":"\u00a9Medicinr\u00e5det. V\u00e6rdis\u00e6tning af enhedsomkost ninger Version 1.7. 2023. Available from: https:\/\/medicinraadet.dk\/media\/gpjgcotu\/v%C3%A6rdis%C3%A6tning-af-enhedsomkostninger-vers-1-7.pdf."},{"key":"3033_CR26","unstructured":"Statistics Denmark. Consumer price index https:\/\/www.dst.dk\/en\/Statistik\/emner\/oekonomi\/prisindeks\/forbrugerprisindeks. Accessed 26 Jan 2024."},{"key":"3033_CR27","unstructured":"Xe currency converter. 2023. https:\/\/www.xe.com\/currencyconverter\/convert\/?Amount=1&From=DKK&To=EUR. Accessed 1 May 2024."},{"key":"3033_CR28","unstructured":"Medicinr\u00e5dets anbefaling vedr. tucatinib i kombi nation med trastuzumab og capecitabin til behan dling af lokalt fremskreden inoperabel eller met astatisk HER2+ brystkr\u00e6ft efter progression p\u00e5 to HER2-rettede behandlinger 2023. Available from: https:\/\/medicinraadet.dk\/anbefalinger-ogvejledninger\/laegemidler-og-indikationsudvidelser\/t\/tucatinib-tukysa-i-komb-med-trastuzumab-og-capecitabin-metastatisk-her2-positivbrystkraeft."},{"key":"3033_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1049947","author":"M Zhan","year":"2023","unstructured":"Zhan M, Huang Z, Xu T, Xu X, Zheng H, Wu F. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1049947.","journal-title":"Front Public Health"},{"key":"3033_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290507","author":"D Shi","year":"2023","unstructured":"Shi D, Liang X, Li Y, Chen L. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer. PLoS ONE. 2023. https:\/\/doi.org\/10.1371\/journal.pone.0290507.","journal-title":"PLoS ONE"},{"key":"3033_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1025243","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu K, Zhu X, Qin Q, Zhu H. Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: a US-based cost-effectiveness analysis. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.1025243.","journal-title":"Front Pharmacol"},{"key":"3033_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231169983","author":"J Yang","year":"2023","unstructured":"Yang J, Han J, Zeng N, Yan X. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor\u00a02-low metastatic breast cancer. Therap Adv Med Oncol. 2023. https:\/\/doi.org\/10.1177\/17588359231169983.","journal-title":"Therap Adv Med Oncol"},{"key":"3033_CR33","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S389696","author":"Y Lang","year":"2022","unstructured":"Lang Y, Wu B, Liu X. Economic evaluation of trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer in the United States. Breast Cancer (Dove Medical Press). 2022. https:\/\/doi.org\/10.2147\/BCTT.S389696.","journal-title":"Breast Cancer (Dove Medical Press)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03033-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:08Z","timestamp":1738234988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03033-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03033-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeroen Hendrikus Jacobus Paulissen, Alexander Victor van Schoonhoven, and Arjan Jacobus Postma are paid employees of Asc Academics; Emma Olin and Zacharie\u00a0Mbanya are paid employees of AstraZeneca; Kyle John Dunton is a paid employee of Daiichi Sankyo International; Marinus van Hulst reports no financial interests; Maarten Jacobus Postma is advisor to Asc Academics. Roel Donald Freriks was an employee of Asc Academics at the time the research was conducted. He is currently employed by IQVIA. Asc Academics received consulting fees paid from Daiichi Sankyo International and AstraZeneca. Maarten Jacobus Postma is a non-remunerated member of the UK\u2019s Joint Committee of Vaccination and Immunization, other authors report no non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}